FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to pharmaceutical composition for modulating the activity of glutaminyl cyclase, and also for treatment of a disorder associated with glutaminyl cyclase activity containing an effective amount of a compound of N,N'-bis[2-(1H-imidazol-4-yl)ethyl]isophthalamide.
.
EFFECT: implementation of invention will yield effective glutaminyl cyclase modulator having a high activity with respect to intracellular and/or secreted isoforms of glutaminyl cyclase and good pharmacokinetic characteristics.
11 cl, 10 ex, 6 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| NEW GLUTAMINE CYCLASE INHIBITOR AND ITS APPLICATION | 2018 |
|
RU2791703C2 |
| NEW INHIBITOR OF GLUTAMINYL CYCLASE AND ITS USE FOR TREATMENT OF LUNG AND RESPIRATORY DISEASES | 2017 |
|
RU2662559C1 |
| NEW ZINC COMPLEX, ITS PREPARATION AND APPLICATION FOR THERAPY OF HUMAN AND ANIMAL DISEASES | 2018 |
|
RU2697580C1 |
| COMPOSITION FOR THE TREATMENT OF FELINE INFECTIOUS PERITONITIS | 2021 |
|
RU2780097C1 |
| METHOD OF IMMUNOCORRESPONDENCE IN CASE OF PURULENT PERITONITIS | 1992 |
|
RU2026678C1 |
| PHARMACEUTICAL COMPOSITION INCLUDING RENIN INHIBITOR, CALCIUM CHANNEL BLOCKER AND DIURETIC | 2003 |
|
RU2316318C2 |
| MCP-1 BINDING NUCLEIC ACID AND USING IT | 2008 |
|
RU2542973C2 |
| G-CSF - CONTAINING AGENT FOR PREVENTION AND TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY | 2007 |
|
RU2448726C2 |
| USE OF GLUTARIMIDE DERIVATIVE FOR THERAPY OF DISEASES ASSOCIATED WITH ABERRANT ACTIVITY OF INTERLEUKIN-6 | 2020 |
|
RU2774928C2 |
| FUSED RAGE PROTEINS | 2008 |
|
RU2513695C2 |
